Webcasts Event RSS
Upcoming Events Past Events
JMP Securities Life Sciences Conference
June 19, 2019
View the live Webcast
Goldman Sachs 40th Annual Global Healthcare Conference
June 12, 2019
View the live Webcast
2019 Bank of America Merrill Lynch Global Healthcare Conference
May 16, 2019
View the live Webcast

Investor Materials

Thumb Date Download
July 20, 2018 Corporate Presentation 1.07 MB
December 31, 2017 2017 Annual Report 3.18 MB
July 24, 2016 2016 Annual Report 4.75 MB
July 23, 2016 2015 Annual Report 5.24 MB
July 21, 2016 2014 Annual Report 2.13 MB

Recent News

Date Title Press Release RSS
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology 07/19/19
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology 07/17/19
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology 07/12/19
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology 06/25/19
See More

Stock Quote

HALO (NASDAQ) $16.29 -0.50 -2.98% Volume: 543,927 Pricing delayed 20 minutes July 19, 2019

Investor Contacts

Al Kildani
Vice President, Investor Relations
& Corporate Communications
Phone: 858-704-8122
Email: akildani@halozyme.com
media@halozyme.com
ir@halozyme.com

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

July 19, 2019 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
July 17, 2019 Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
July 12, 2019 Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Copyright © 2015-2017 . Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.23.3.1

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok